Giffin Brett A. 4
4 · T2 Biosystems, Inc. · Filed Mar 9, 2023
Insider Transaction Report
Form 4
Giffin Brett A.
Chief Commercial Officer
Transactions
- Sale
Common Stock
2023-02-22$0.65/sh−537$349→ 841 total - Exercise/Conversion
Common Stock
2023-02-20+1,333→ 1,378 total - Exercise/Conversion
Restricted Stock Units
2023-02-20−1,333→ 2,667 total→ Common Stock (1,333 underlying)
Footnotes (3)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- [F2]The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person adopted by the reporting person on November 10, 2021.
- [F3]On February 20, 2022 the reporting person was granted 4,000 RSU's that vest in three equal annual installments commencing on February 20, 2023